Put companies on watchlist
Bio-Gate AG
ISIN: DE000BGAG981
WKN: BGAG98
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Bio-Gate AG · ISIN: DE000BGAG981 · EQS - Company News (3 News)
Country: Germany · Primary market: Germany · EQS NID: 1143538
28 October 2020 09:00AM

Bio-Gate AG: Bio-Gate successfully markets antiviral and antibacterial Protective Film Spray for surfaces


DGAP-News: Bio-Gate AG / Key word(s): Product Launch/Miscellaneous
Bio-Gate AG: Bio-Gate successfully markets antiviral and antibacterial Protective Film Spray for surfaces

28.10.2020 / 09:00
The issuer is solely responsible for the content of this announcement.



PRESS RELEASE

Bio-Gate successfully markets antiviral and antibacterial Protective Film Spray for surfaces

- Protective Film Spray from Bio-Gate used for the first time in public transport in Nuremberg
- Advanced negotiations with further potential customers
- Successful commercialization for use in schools, public transport, banks and fitness studios


Nuremberg, 28. October 2020 - Bio-Gate AG (ISIN DE000BGAG981), one of the world's leading suppliers of innovative technologies and individual solutions for health and hygiene, has successfully launched the new antiviral and antibacterial MSGB-Tec Protective Film Spray. The spray is being used in the public transport system in Nuremberg to supplement the existing hygiene measures.

This was preceded by a successful field study in buses, in which the Protective Film Spray showed a high and lasting efficacy. Even more than a week after spraying, a germ reduction of around 90 percent was measured on the handrails, straps, handles and seats of the buses that were tested. This was achieved under the normal, daily use of the buses during passenger transport. In addition to its lasting effect, Bio-Gate's Protective Film Spray is skin-friendly and easy to apply. Besides the handrails and handles, the spray can also be applied to the seats and other textile surfaces. If the technology is applied e.g. directly after basic cleaning, the hygiene status can be maintained or extended for a longer period of time, as cleaning and disinfection measures usually do not last long.

VAG in Nuremberg is one of the first adopters of the MSBG-Tec impregnation spray in Germany, along with another domestic transport company and customers abroad. Follow-up orders are in preparation. The spray application is always verified by a certified test laboratory that checks the effectiveness of the treatment.

The MSGB-Tec Protective Film Spray has been proven to inactivate enveloped viruses. In addition to the current corona virus (SARS-CoV-2), these include SARS-CoV, MERS-CoV and flu viruses. It represents a modern concept for a more sustainable treatment that strengthens the effectiveness of existing cleaning cycles and it is suitable for COVID-19 prevention. The spray also has an antibacterial effect and has an odour-binding technology that immediately reduces unpleasant odours in mass transport vehicles.

The use of Bio-Gate's solutions in public institutions and local public transport is a forward-looking measure to respond to the second wave of increasing COVID-19 infection rates. Especially in public transport, the safety of passengers can be further increased with additional passive hygiene standards. In addition to the use of the spray, Bio-Gate organises regular hygiene monitoring, which is carried out by a certified laboratory from Nuremberg on a random basis in all means of transport or other public facilities.

Thomas Konradt, Director of Business Development at Bio-Gate AG, says: "The MSGB-Tec Protective Film Spray is a registered product, through the use of which our customers achieve a guaranteed high-quality hygiene management in a natural way. Our technology is antiviral, antimicrobial and odour-binding. It also has a lasting effect". Marc Lloret-Grau, CEO, adds: "We are very pleased that we have already convinced the first customers of our solutions. In addition to local and long-distance passenger transport, the Protective Film Spray can also be easily and effectively used in public institutions, schools and cinemas to supplement the existing hygiene strategy in these facilities. In this way, we are making a contribution by providing people in enclosed spaces with the highest possible level of safety during these challenging times and we are enabling a return to normality despite corona".


Contact:
Bio-Gate AG
Neumeyerstr. 28-34
D-90411 Nuremberg, Germany
www.bio-gate.de

North America:
Karl Richter
RFH BioTek Inc.
Tel: 416-407-6120
rfh@rfhBioTek.com
Toronto, Canada

Gerd Rückel
rikutis consulting
gr@rikutis.de
presse@bio-gate.de
Tel +49 (0) 6172 807309
Mobile +49 (0)152 34221966

About Bio-Gate:
The health technology company Bio-Gate AG is one of the world's leading providers of innovative technologies and individual solutions for health and hygiene, which can make living together safer, more carefree and healthier and improve the well-being of every individual. It specialises in equipping materials and surfaces with antiviral and antimicrobial properties. Bio-Gate AG refines materials and products, especially in the field of medical technology, such as the coating of implants or wound dressings. In addition, Bio-Gate technologies are used to make cosmetics, consumer and industrial products, such as paints and varnishes or plastics antimicrobial, thus enhancing them in a unique way.

Disclaimer:

This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the "Shares") may not be offered or sold in the United States or to or for the account or benefit of "U.S. persons" (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")). The securities have already been sold.



28.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Bio-Gate AG
Neumeyerstr. 28-34
90411 Nürnberg
Germany
Phone: +49 (0) 911 / 47 75 23 - 100
Fax: +49 (0) 911 / 47 75 23 - 101
E-mail: marc.lloret-grau@bio-gate.de
Internet: www.bio-gate.de
ISIN: DE000BGAG981
WKN: BGAG98
Listed: Regulated Unofficial Market in Berlin, Munich, Stuttgart
EQS News ID: 1143538

 
End of News DGAP News Service

1143538  28.10.2020 

fncls.ssp?fn=show_t_gif&application_id=1143538&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Bio-Gate AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.